The recent development of lipid-lowering drugs is very popular. A new lipid-lowering drug ETC-1002 from Esperion Therapeutics not only outperformed Merck's Zetia （generic name: Ezetimibe） in a mid-term clinical trial, but more importantly, the compound combination of the two performed better Lipid-lowering effect. On October 2, the Lancet reported two key clinical outcomes of the Amgen PCSK9 inhibitor Evolocumab （Rutherford-2 and Tesla PartB）. In a randomized, double-blind, placebo-controlled, multicenter clinical trial （Rutherford-2）, Evolocumab, combined with a statin lipid-lowering agent or Zetia, was able to reduce LDL in patients with familial heterozygous hypercholesterolemia （FH） Levels were reduced by 60%, and these patients were not able to reduce their LDL levels to the recommended levels even with high-dose statin therapy combined with Zetia. The latter Tesla Part B trial recruited more severe and rare patients with homozygous hypercholesterolemia and reduced LDL levels in these patients by 31%, with no significant increase in adverse events in the treatment group. In addition, clinical outcomes of acute coronary syndromes with Simvastatin （simvastatin） and Vytorin （a combination of simvastatin and Zetia） were compared in a head-to-head study involving 18,000 subjects （IMPROVE-IT ） Is ex